Plasma Fractionation Market Size Is Expected to Rise to USD 87.23 billion by 2034, with a CAGR of 9.1% During the Forecast Period; Prevalence of Immune and Rare Disorders to Propel Market Progress

The global plasma fractionation market size was valued at USD 40.27 billion in 2025. The market value, further, is predicted to grow from USD 43.55 billion in 2026 to USD 87.23 billion by 2034, with a CAGR of 9.1% from 2026 to 2034. Fortune Business Insights™ presents this information in its report titled “Plasma Fractionation Market Size, Share & Industry Analysis, By Product (Albumin, Immunoglobulin {IVIG and SCIG}, Coagulation Factors {Factor IX, Factor VIII, and von Willebrand Factor}, and Protease Inhibitors {Alpha-1 Antitrypsin and C1 Esterase Inhibitor}), By Application (Immunology, Neurology, Hematology, Critical Care, and Pulmonology), By End User (Hospitals & Clinics, Specialty Clinics & Infusion Centers, and Homecare Settings), and Regional Forecast, 2026-2034”

Plasma fractionation, a significant technique, employed for the treatment of immune disorders, blood clotting disorders, metabolic deficiencies, and other life-threatening disorders. The technique has continuously played a crucial part in producing plasma-derived medicines for treating immune deficiencies, neurological disorders, bleeding conditions, critical care needs, and rare protein-deficiency diseases. As the network of plasma collection centers expands, the global market is set to witness a wave of opportunities. The expansion is set to fulfil the increasing demand for immunoglobulins, albumin, coagulation factors, and specialty plasma proteins.

Kedrion and Portuguese Institute of Blood and Transplantation (IPST) Collaboration to Augment the Kedrion’s Standing

In July 2024, Kedrion and Portuguese Institute of Blood and Transplantation (IPST) collaborated for enabling Portuguese hospitals with medicines that Kedrion produces by fractionating Portuguese plasma from blood donations from charitable donors. The initiative has been treated as a major national initiative for Portugal to become self-sufficient in plasma-derived medicines.

Shift Towards Self- Sufficient Production of Plasma-Derived Medicines to Boost the Market Growth

One of the prominent market trends to be observed is the shift of the market towards national plasma self-sufficiency. This is exemplified by Takeda’s announcement of capital investment worth USD 230.0 million in June 2024, for expanding the production capacity of plasma-derived therapy at its Los Angeles manufacturing site. As governments and healthcare systems aim to reduce dependence on imported plasma-derived medicines, the trend will encourage long-term manufacturing contracts, local plasma collection, and investments in fractionation capacity.

The plasma fractionation market growth, on the other hand, is facing challenges derived through the complex and time-consuming manufacturing process of plasma-derived medicines.

Key Players Are Defining The Market Competition Through Product Launches, Plasma Collection Expansion, And Regional Partnerships

The global plasma fractionation market’s competitive landscape is characterized by the presence of large plasma-derived therapy manufacturers with strong abilities in plasma collection, fractionation, purification, and specialty biologics commercialization. CSL Behring, Grifols, Takeda, Octapharma, Kedrion Biopharma, LFB, ADMA Biologics, and GC Biopharma are actively competing through product launches, label expansions, plasma collection expansion, capacity investments, and regional supply partnerships.

Key Players Profiled in the Report

• CSL (Australia)
• Grifols, S.A. (Spain)
• Takeda Pharmaceutical Company Limited (Japan)
• Octapharma AG (Switzerland)
• Kedrion S.p.A. (Italy)
• LFB Group (France)
• ADMA Biologics, Inc. (U.S.)
• GC Biopharma (South Korea)
• Beijing Tiantan Biological Products Co., Ltd. (China)
• Shanghai RAAS Blood Products Co., Ltd. (China)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614

Key Industry Development

• November 2025: Baiyang Pharmaceutical collaborated with CSL Behring for providing former with exclusive promotion, sales, and distribution rights for CSL Behring's human albumin product, Alprolix, in specific countries within China except Hong Kong, Macau, and Taiwan.

Further Report Findings

• North America, in 2024 and 2025, took the position of leading region in the plasma fractionation The sustaining dominance is attributed to high plasma collection capability, high use of immunoglobulin therapies, and well-established reimbursement for rare and immune disorders.
• Europe, projected to grow by 8.1% over the forecast period, with growth supported by the government’s focus on plasma self-sufficiency, is also encouraging local collection and fractionation partnerships. The German and U.K. market in 2026 are estimated to touch USD 90 billion and USD 1.46 billion, respectively.
• Immunoglobulins was the leading product in the plasma fractionation market share. They are widely used in the treatment of primary immunodeficiency, secondary immunodeficiency, autoimmune disorders, and neurological conditions including CIDP. In addition, albumins are projected to grow at a 7.8% CAGR during the forecast period.

Table of Segmentation